Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06782971

Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

Sponsor: Clinical Hub for Interventional Research (CHOIR)

View on ClinicalTrials.gov

Summary

The goal of this observational study is to develop new ways to test new drug combinations to kill tumour cells, in patients with acute myeloid leukemia (AML). The main questions it aims to answer are: * Are there new ways to speed up discovery of better treatments for AML patients using AML cells from individual from patients in special mice that can accept human tissue? * Do these mice show treatment responses that are similar to the individual AML patient from whom cells were derived? Participants with AML who are taking standard of care treatment of venetoclax and azacitidine will be asked to donate blood and bone marrow samples for this study.

Official title: COSMOS-Avatar: Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

25

Start Date

2025-06-06

Completion Date

2030-03

Last Updated

2025-12-08

Healthy Volunteers

No

Locations (4)

Canberra Health Services

Canberra, Australian Capital Territory, Australia

Prince of Wales Hospital

Sydney, New South Wales, Australia

Royal North Shore Hospital

Sydney, New South Wales, Australia

Westmead Hospital

Westmead, New South Wales, Australia